Introduction {#Sec1}
============

Hepatitis A was a term first introduced by Krugman et al*.* in 1967 (Krugman et al. [@CR21]), and there is still a moderate-to-high risk for hepatitis A in the majority of the world's population (Victor et al. [@CR36]). Approximately 1.4 million cases of hepatitis A occur every year worldwide, predominantly in developing countries (Di Giammarino and Dienstag [@CR8]). Consequently, it is responsible for a substantial economic burden to society in terms of direct treatment cost and indirect productivity loses (Keystone and Hershey [@CR17]). This disease is caused by Hepatitis A virus (HAV) which belongs to the genus *Hepatovirus* of the *Picornaviridae* family that primarily infects hepatocytes. It can cause effects that range from the slight symptoms such as fever, anorexia, nausea to death from fulminant hepatitis (Martin and Lemon [@CR27]). Transmission of HAV is mainly through the faecal--oral route by contaminated water and food in global perspective (Hadler et al. [@CR13]). However, in some areas, e.g., the United States, the most common reported source of infection is household or other close contact with an infected person (Victor et al. [@CR36]).

Hepatitis A vaccines have been licensed since 1992 and currently provide pre-exposure protection from HAV infection (CDC [@CR4]). They are long-term protective and highly immunogenic in both children and adults (Van Damme and Van Herck [@CR35]). The administration of Immunoglobulins (Igs) provides short-term effective protection (Larralde et al. [@CR22]). It is mainly for people exposed to the high risk of infection, such as people traveling to places where the virus is endemic or who have close personal contact with a Hepatitis A patient (Kim et al. [@CR18]). Furthermore, Igs are the only product recommended for post-exposure prophylaxis in the United States and Igs administered intramuscularly is the product used for the prevention of HAV infection (CDC [@CR5]). However, Igs against HAV is mainly derived from human plasma, which led to limited supply and possible healthy risks due to its impurity. Therefore, the application of human monoclonal antibodies (mAbs) has been considered as an alternative approach against HAV infection, because mAbs have proven to be the well-characterized and highly effective products with better activity than their polyclonal counterparts (Lonberg [@CR24]; Marasco and Sui [@CR26]).

Through nearly 30 years of development, mAbs have progressively played an important role in therapeutic strategies (Reichert et al. [@CR31]). Accordingly, the rapidly growing market demand has driven a wide range of mAbs applications. Even with conservative prediction, mAbs will probably have global sales of \$20 billion by the year 2010 (Gottschalk [@CR12]). The platforms for the mAbs production are variable but critical owing to the significant impact on the level and quality of the products (Keefer [@CR16]). Most of the mAbs approved for commercialization are currently produced by mammalian cell culture; however, this system faces a shortage of production capacity and scale-up production will be inevitably associated with extremely high costs. Besides, in different culture conditions, there are pitfalls in complicated purification steps as well as variable mAbs levels and post-translational modifications (Castillo [@CR3]; Farid [@CR11]; Kozlowski and Swann [@CR20]; Winokur and Stapleton [@CR39]). These limitations have motivated researches to develop alternative production technologies with higher efficiency.

Technology advances in genetic engineering opened up a way for the cost-effective, large-scale production of mAbs using the mammary gland of transgenic animals. This method is capable of high level expression at low cost, associated with the required complex post-translational modifications, constant secretion and stable bioactivity of these proteins. Thus this production system can avoid the pitfalls associated with other expression systems and makes transgenic production of mAbs attractive (Dove [@CR9]; Dyck et al. [@CR10]; Houdebine [@CR15]). In recent years, there have been many successful examples of mAbs expression in the milk of transgenic mice with production levels of up to several mg per ml; such as mAbs against Coronavirus, Hantavirus, CD20 and CD69 (Castilla et al. [@CR2]; Molina et al. [@CR28]; Sola et al. [@CR33]; Tang et al. [@CR34]; Yu et al. [@CR41]). Moreover, it is noteworthy that recombinant human antithrombin III produced in the mammary gland of transgenic goats has been approved as a drug by the European Medicines Evaluation Agency (EMEA) in 2006, which launched as ATryn in the treatment of blood clotting. This demonstrates the commercial reality of protein mass-production by transgenic animals. Therefore in this paper, we expressed a human mAb in the milk of transgenic mice, and explored its potential effect on immunoprophylaxis of HAV infection. This study aimed to demonstrate the feasibility for a large-scale production of the mAbs against HAV in the milk of transgenic farm animals in the future.

Materials and methods {#Sec2}
=====================

Construction of transgenes {#Sec3}
--------------------------

The coding regions of H chain (HC) and L chain (LC) genes of a human IgG1 mAb against HAV were amplified by PCR from plasmids pHAVH3 and pHAVL3 (Wei et al. [@CR37]). The HC was amplified using primers HC-F (5′-GT*CTCGAG*CCATGGGATGGAGCTGTA-3′) and HC-R (5′-GT*CTCGAG*AGATTATTTTCCCGGACT-3′), both containing a *Xho*I site. Primers LC-F (5′-GT*GTCGAC*CCATGGGATGGAGCTGTA-3′) and LC-R (5′-GT*GTCGAC*ACTAGTCCCTC TAACACT-3′), both with an added *Sal*I site were used to amplify the LC. Then the two amplified fragments were separately cloned into the expression plasmid pBC1 digested with *Xho*I. The resulting plasmids designated pBC-hGHC and pBC-hGLC were under the control of the goat β-casein regulatory sequences to direct gene expression specifically in the mammary gland duration lactation.

Generation of transgenic mice {#Sec4}
-----------------------------

The hGHC and hGLC transgenes were, respectively, released from the plasmids with *Not*I/*Nru*I or *Not*I/*Sal*I digestion, leading to a 18.1 kb or a 16.5 kb DNA fragment, containing of chicken β-globin insulator, goat β-casein promoter, Ig secretory leader, either the human VH-Cγ1 gene (with introns) or VL-Cκ gene, and β-casein 3′ genomic DNA, respectively (Fig. [1](#Fig1){ref-type="fig"}). These two fragments were purified after agarose gel electrophoresis (Omega, USA) and subsequently co-microinjected at a 1:1 molar ratio into pronuclei of fertilized Kunming White eggs according to standard protocols. Genomic DNA was extracted from tail biopsies of mice as described previously (Hogan et al. [@CR14]). The presence of the transgenes was identified by PCR with primers pBC-F (5′-GATTGACAAGTAATACGCTGTTTCCTC-3′) and pBC-R (5′-CATCAGAAGTTAAACAGCACAGTTAG-3′). The primers were specific to the β-casein intron 1 and intron 7 sequences and could therefore detect both heavy and light chain genes simultaneously. Genomic DNA (10 μg) was digested with *Eco*RI and analyzed by Southern blotting (Sambrook and Russell [@CR32]) with the hybridization probes labelled by \[α-^32^P\] dCTP. The probes were the amplified products of 2.4 kb HC and 1.2 kb LC genes. Transgene copy numbers were determined by signal quantification via a phosphorimager (Storm 820; Molecular Dynamics, Sunnyvale, CA).Fig. 1Schematic presentation of the hGHC/hGLC transgene constructs used for microinjection. **a** Structure of the transgene construct released from pBC1 vector with *Not*I*/Nru*I for HC and *Not*I*/Sal*I for LC. The transgene backbone contains 2 × chicken β-globin insulator, goat β-casein promoter, untranslated exons (E)1, parts of E2 and 7, E8, E9 and β-casein 3′ genomic DNA. The dotted lines indicate insertion of the HC and LC sequences to the unique *Xho*I restriction site, respectively. **b** Hatched boxes and solid boxes represent Ig secretory leader and the variable regions (VH and VL), respectively. Exons encoding the constant regions as open boxes are indicated in CH1, Hinge, CH2 and CH3 for HC or Cκ for LC. Translational start codons are indicated in the H chain and the L chain of Ig, respectively. Relevant restriction enzymes sites are shown

### RT-PCR analysis {#Sec5}

Total RNA was isolated using Trizol (Tiangen, CN) from mammary glands tissues of three female transgenic mice during lactation periods. One microgram of total RNA was used for first-strand cDNA synthesis by using M-MLV Reverse Transcriptase (Progema, USA). The reaction was carried out for 1 h at 37°C for oligodT in a total volume of 25 μl. Primers used to detect the chimeric mRNA expression were Exon1-F (5′-TCCATTCAGCTTCTCCTTCA-3′) and VH-R (5′-CCTCGGCTCTCAGATTGTTC-3′), Exon1-F (5′-TCCATTCAGCTTCTCCTTCA-3′) and VL-R (5′-GACTTGGAGCCAGAGAATCG-3′), which were complementary to the exon 1 of the goat β-casein gene and V-region of the HC and LC, amplifying 408 bp and 322 bp fragments, respectively. The mouse β-actin was used as RT-PCR internal control. The primers of mouse β-actin were β-actin F (5′-TTCTACAATGAGCTGCGTGTGG-3′) and β-actin R (5′-GGTGTTGAAGGTCTCAAACATGAT-3′), amplifying a 142 bp fragment.

SDS-PAGE {#Sec6}
--------

Milk from transgenic mice and non-transgenic mice was collected at day 7 and 20 of lactation, diluted with distilled water to 500 μl, and defatted by centrifugation at 4°C or 15 min at 10,000×*g*. The skim milk obtained was mixed with sample buffer and then separated on 10% SDS-PAGE gels under both reducing and non-reducing conditions, respectively. Proteins were visualized by staining with Coomassie brilliant blue.

Western blotting {#Sec7}
----------------

Separated proteins were electrophoretically transferred to nitrocellulose membranes (Amersham Pharmacia, UK), and then incubated overnight in blocking buffer (3% BSA in PBS-T) at 4°C. Immunodetection was carried out with the HRP-conjugated goat anti-human Fab specific antibody (Sigma, US) and ECL western blotting reagents (Amersham Biosciences, UK) according to the manufacturer's instructions. Purified human IgG (Sigma, US) was used as the positive control.

ELISA {#Sec8}
-----

A 96-well microtitre plate was coated with goat anti-human Fab (Sigma, US) and incubated at 4°C overnight. After being washed with PBS containing 0.05% Tween-20 (PBS-T), the wells were blocked with 0.5% BSA in PBS-T for 2 h at room temperature. One hundred microliters of milk samples were added per well at twofold serial dilutions from 1/1,000 to 1/512,000, respectively. After the incubation and washing, plates were incubated with 100 μl of HRP-conjugated goat anti-human IgG Fc antibody (Sigma, US) at a dilution of 1/2,000 per well. A standard curve was generated using twofold serial dilutions of purified human IgG. The colorimetric reaction was developed with the substrate TMB (Pierce, US) and the absorbance value was measured at 450 nm. The plate was washed six times in PBS-T between each step and all incubations were carried out at room temperature for 1 h. The specific binding activity of the milk samples to HAV antigen was determined by ELISA using purified Hepatitis A antigen (Cao et al. [@CR1]) coated microtitre plates. HRP-conjugated anti-human Fc specific antibody at a 1/2,000 dilution was used. The HA78 antibody (2.5 mg/ml), which was expressed by CHO cells, was used as the positive control.

In vitro neutralization activity test {#Sec9}
-------------------------------------

Neutralizing activity against HAV was determined in a modified cell culture assay, based on MacGregor et al. ([@CR25]). First, HAV JN strain was diluted in 10-fold steps from 10^−1^ to 10^−5^ to determine the 50% tissue culture infective dose (TCID~50~) in fetal rhesus monkey kidney (FRhK-4) cells; then the titre of infectious virus was determined based on the TCID~50~ endpoint. 100TCID~50~ of HAV were used for the following experiment. The milk samples were initially diluted to the concentration close to 2.5 mg/ml. Then, both the milk samples and recombinant purified antibody (positive control, 2.5 mg/ml) were diluted using twofold dilutions from 1/20 to 1/640, and were incubated with 0.1 ml of virus at 37°C for 2 h separately. Four replicates of each sample were inoculated onto the monolayers of FRhK-4 cells growing in 24 wells plates. Mock infected cells were included as HAV negative control. In addition, HAV virus titre was also measured by ELISA. After all the plates were incubated at 33°C for 1.5 h and the medium removed, 1.0 ml of fresh culture medium was added to the wells of each plate. Monolayers were further incubated for 21 days and the culture medium was replaced every 6--7 days. The cells were harvested after 21 days, with 0.2 ml of PBS plus 0.05% of Tween-20 and disrupted by three cycles of freeze--thawing. The presence of HAV was monitored by ELISA with the condition that polyclonal human anti-HAV antibody (CDC, CN) was used as coating antibody and HRP-conjugated polyclonal human anti-HAV antibody (CDC, CN) used as detecting antibody. The 50% neutralization endpoint was calculated (Reed and Muench [@CR30]).

Results {#Sec10}
=======

Generation of the transgenic mice {#Sec11}
---------------------------------

To generate transgenic mice expressing the anti-HAV mAb at high levels in milk, two separate cassettes were constructed encoding the IgG HC and LC genes, each under control of the goat β-casein promoter (Fig. [1](#Fig1){ref-type="fig"}). These two cassettes were co-injected into the fertilized mouse eggs. Four males (No. 1, 2, 14, 15) and 4 females (No. 7, 8, 9, 35) transgenic founders were obtained from 36 mice analyzed by PCR (Fig. [2](#Fig2){ref-type="fig"}a); all contained both the HC and LC transgenes. In addition, there were another five founders containing either HC or LC transgenes; these were not analyzed further.Fig. 2Molecular characterization of transgenic mice. **a** PCR detection of transgenic founders. M, 1 kb DNA ladder; P: positive plasmid control; NC, negative control; transgenic founders numbered 1, 2, 7, 8, 14, 15 and 35. The amplified products are 2.4 kb for HC and 1.2 kb for LC. **b** Southern blot analysis of the transgenes. The digested genomic DNA was hybridized with the mixture probes of amplified HC and LC fragments and hybridization signals for HC and LC are indicated. NC, genomic DNA of non-transgenic mice as a negative control; P1, P3, P5, are positive plasmid DNA equivalent to 1, 3 and 5 gene copies, respectively. The transgene copy numbers are presented in Table [1](#Tab1){ref-type="table"}. **c** RT-PCR analysis of the transgenes expression in the mammary gland tissues of transgenic mice. RT-PCR was performed to demonstrate the presence of the chimeric mRNA. M, 100 bp ladder; Transgenic mice are 7, 9 and 14--43; NC, the non-transgenic mouse. The mouse β-actin gene was used as the internal control

Southern blotting was further used to confirm that both transgenes were integrated into the genome of all eight transgenic mice (Fig. [2](#Fig2){ref-type="fig"}b) as well as to determine the transgene copy number. The probes specific for 2.4 kb HC and 1.2 kb LC fragments were mixed together allowing both transgenes to be detected simultaneously, enabling comparison of the relative copy numbers. The copy numbers of the transgenes in eight founders were different, ranging from 3 to 20 for both HC and LC by comparing with the band intensity with those of known amount of control plasmids (Table [1](#Tab1){ref-type="table"}). Six transgenic founders (8 and 35 died) were mated with wild type mice and all of them transmitted the transgenes to their offspring. A total of 26 F1 transgenic mice were identified among 54 offspring, 15 of them contained double transgenes, while the remaining contained either the HC or LC transgene. This probably reflects multiple integration loci in some founder animals.Table 1Correlation of the transgene copy number and mAb concentration in different transgenic linesLine F0 (Sex)Offspring F1^a^Copy No.^b^Expression level (mg/ml)^c^HCLC7 (F)5522.39 (F)151017.69--49 (F)32.29--50 (F)6.714 (M)3314--43 (F)16.515 (M)202015--24 (F)75.3 × 10^−3a^Offspring F1 refers to the F1 progeny of founders^b^Transgene copy number was determined as described in ["Material and methods"](#Sec2){ref-type="sec"}^c^The expression levels are presented based on the ELISA assay

Expression of the anti-HAV mAb in the mammary glands of transgenic mice {#Sec12}
-----------------------------------------------------------------------

The HC and LC transgenes mRNA expression in the mammary gland of lactating transgenic mice were analyzed by RT-PCR (Fig. [2](#Fig2){ref-type="fig"}c). We found that both the HC and LC transgenes were expressed in the females of three detected transgenic lines (mice 7, 9 and 14--43). This result confirmed that the recombinant mAb was expressed from the chimeric mRNA, which contains untranslated exons 1 and 2 of the goat β-casein gene.

Milk samples were collected from five transgenic founder mice or F1 mice that carried both transgenes. The structure and expression of the anti-HAV mAb in the milk was analyzed by western blotting. A single band was detected for both the HC and LC under reducing condition with the expected molecular weights (MW) of 50 kDa (HC) and 25 kDa (LC), respectively (Fig. [3](#Fig3){ref-type="fig"}a). The results indicated the presence of the HC and LC expression in all the detected lines. Transgenic milk samples were also analyzed under non-reducing conditions which showed strong bands with the MW of 150 kDa (Fig. [3](#Fig3){ref-type="fig"}b). The relative molecular mass of the major detected bands were identical to the purified human IgG, indicating that the recombinant mAb was assembled and modified correctly in these transgenic mice. However, some additional weak bands with lower MW were also observed, probably reflecting the presence of incompletely assembled IgG molecules.Fig. 3Western blot analysis of transgenic lines expressing the recombinant mAb against HAV. The milk samples were separated by SDS-PAGE under reducing (**a**) and non- reducing conditions (**b**). Following transferred to the nitrocellulose membranes, samples were detected with HRP-conjugated goat anti-human Fab specific antibody. Molecular weight markers were indicated in the left lane. 2, 7, 9, 9--49, 14--43, 15--24, different transgenic mice; NC, negative control (milk of non-transgenic mice); PC, positive control (purified human IgG)

The stability of the mAb production in the milk was also detected by analyzing eight mice (F2 generation) in four transgenic lines. Within each line, the amount of mAb was constant (data not shown). This result may be due to the co-integration of both transgenes in the same chromosome for most of the founders.

To assess the expression levels of the recombinant mAb, the skim milk obtained at day 7 and 20 of lactation periods from four different transgenic lines (Line 7, 9, 14 and 15) was measured using an ELISA approach specific to human IgG Fab fragment. Four lines were shown to express the anti-HAV mAb higher than 1 mg/ml with the highest level was up to 32.2 mg/ml. Line 15 showed a low expression level (Table [1](#Tab1){ref-type="table"}). No apparent differences in expression of the mAb were observed between the milk samples collected on day 7 and those collected on day 20 in each line (data not shown).

Characterization of the mAb binding specificity to HAV antigen {#Sec13}
--------------------------------------------------------------

The binding specificity of the milk samples to HAV antigen was examined by ELISA. As expected, the milk samples could bind to HAV antigen in a dose-dependent manner and their affinities for HAV appeared to be equivalent (except line 15) which had nearly the same binding specificity as CHO-derived IgG (HAIgG78) (Fig. [4](#Fig4){ref-type="fig"}). The highest antibody titer could reach 10^6^ with a concentration of 2.5 ng/ml.Fig. 4ELISA detection of the expressed mAb binding activity to HAV antigen. Dilutions of the milk samples from three transgenic lines 9, 14 and 15 (mice 9, 9--49, 14--43 and 15--24), and a female non-transgenic mouse (negative control) were added to microtitre wells coated with HAV. The specificity was detected with HRP-conjugated anti-human Fc specific antibody. Those legends with D7 and D20 denotes the corresponding milk samples collected at 7th and 20th day of lactation, respectively. The CHO-derived HAIgG78 antibody (2.5 mg/ml), which recognize HAV antigen, was used as the positive control. Values are presented as OD value at 450 nm

To further evaluate the neutralizing activity of mAb, milk from two high expressing transgenic lines, line 9 and 14, was assayed by neutralizing test based on their ability to block HAV infection in FRhK-4 cells. Dilutions of transgenic skim milk were considered to have virus-neutralizing activity if less than 50% of the FRhK-4 cells were infected by HAV. It was shown that all the three transgenic milk samples exhibited neutralizing activity against HAV in a dose-dependent manner (Fig. [5](#Fig5){ref-type="fig"}). In particular, the milk sample of mouse 9 reduced HAV infectivity by 50% at a dilution of 1/280, while the milk samples of mice 9--49 and 14--43 reduced HAV infectivity by 50% at a dilution of 1/320. For the milk sample of mouse 9--49, the concentration of the recombinant mAb required for 50% protection was estimated to be 0.3 μg/ml at a dilution of 1/320.Fig. 5Comparison of the specific activity of the recombinant mAbs in HAV neutralization. Serial dilutions from 1/20 to 1/640 of the milk samples (initially diluted to the concentration of 2.5 mg/ml) from two transgenic lines 9 and 14 (mice 9, 9--49, 14--43), and a female non-transgenic mouse (negative control) were assayed with HAV JN strain. The CHO-derived HAIgG78 (2.5 mg/ml) antibody, was used as the positive control

No obvious differences were observed in the neutralizing activity among the detected milk samples. In addition, protection levels were similar to HAIgG78. In contrast, milk samples from non-transgenic mice had no virus neutralizing capacity at any of the tested dilutions.

Discussion {#Sec14}
==========

Towards engineering passive immunization in order to protect HAV infection in human beings, a transgenic mice model expressing the human anti-HAV mAb has been constructed. In this paper, we demonstrate that both the HC and LC of the anti-HAV antibody can be expressed in the milk of transgenic mice under control of the goat β-casein promoter, as well as be properly assembled into functional IgG molecule against HAV. We incorporated two strategies into vector design to enhance transgene expression. First, the chicken β-globin insulator is predicted to reduce the influence of neighboring regulatory elements, thereby it modulating the positive effects caused by the random integration of the transgenes in the host chromosome (Chung et al. [@CR6]). Secondly, genomic rather than cDNA fragments of IgG constant regions were used to benefit from potential enhancer-like effects of its introns (Whitelaw et al. [@CR38]). The high levels of mAb expression that we observed were consistent with the results using these two strategies, though position effects, e.g., line 15 with extremely low expression level, were still observed. Furthermore, most of the mice carried both transgenes, however, when mating the founder transgenic mice with the non-transgenic mice, the resulting single chain of the transgenic offspring might be due to the segregation of the transgenes from different chromosomal sites for some founders. The majority of the transgenic founders transmitted both transgenes to their offspring, which agrees with most of previous studies reported that co-microinjection normally led to both transgenes co-integrated into a single chromosomal site (Clark et al. [@CR7]; Tang et al. [@CR34]).

The amount of the expressed mAb estimated by ELISA in the milk revealed the expression level was higher than any other mammalian expression systems, with the highest expression level up to 32.2 mg/ml. This expression level is considerably higher than those previously reported in the milk of transgenic mice; such as 0.4 mg/ml (Limonta et al. [@CR23]), 0.7 mg/ml (Kolb et al. [@CR19]), 0.8 mg/ml (Newton et al. [@CR29]), 5 mg/ml (Castilla et al. [@CR2]), and 6 mg/ml (Sola et al. [@CR33]). The expression level was maintained over the lactating periods, which validated the fact that goat β-casein promoter could stably drive high level expression of the recombinant proteins to the mammary gland at the lactating stage (Young et al. [@CR40]). No direct relationship between the transgene copy number and the amount of mAb was observed in the detected transgenic mice, implying that the integration site of the transgene had a greater effect on the expression level than that of transgene copy number (Table [1](#Tab1){ref-type="table"}) which is consistent with the previous finding (Sola et al. [@CR33]).

Like other therapeutic recombinant proteins, we have to characterize mAb well in order to ensure their structural and functional activity. Specifically, in our experiment, presence of additional weak bands in the western blotting under non-reducing condition indicated that there were small portion of the incompletely folded IgG molecules. Several explanations have been proposed to interpret this phenomenon; we suggest the most likely explanation relates to the presence of free sulfhydryl in the mAb (Zhang and Czupryn [@CR42]). Each IgG molecule consists of two heavy and two light chains covalently linked by interchain disulfide bonds, with in addition, each domain of the heavy or light chain containing one additional disulfide bond. Some mAb species containing free sulfhydryl are likely to be formed during the protein folding process in the endoplasmic reticulum. Consequently, in our experiment, minor proportion of the formed recombinant mAb in the epithelial cells in the mammary gland of mice may lack interchain disulfide bonds but remain noncovalently associated under non-reducing conditions presenting as low MW fragments in our analysis.

Noteworthily, our data exhibits significant advantages in producing the neutralizing mAb against HAV in the transgenic milk with high-affinity and high-specificity in protein synthesis, as compared with the previously study proposed production of neutralizing mAbs to HAV using phage-displayed antibody library (Kim et al. [@CR18]). The antigen-binding activity of mAb was demonstrated in the specific ELISA, which represented a nearly 40-fold increase in the antibody affinity. Through a virus neutralization assay with previously tested CHO-derived HAIgG78 as the control, we verified that transgenic milk produced mAb was as effective as the HAIgG78 in neutralizing HAV and preventing infection of FRhK4 cells (Fig. [5](#Fig5){ref-type="fig"}).

In conclusion, we have generated transgenic mice expressing high levels of HAV neutralizing mAb in milk. This work solidifies the concept of using larger transgenic animals for the production of a potentially therapeutic anti-HAV antibody. With the ever-growing market need for large quantities of mAbs, transgenic large animals will provide a cost-competitive large-scale production alternative for these complex proteins. Furthermore, this method will also facilitate the commercial production of mAbs using transgenic bioreactors for immunoprophylaxis.
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